top of page
Akthelia has a portfolio of small molecule candidate therapeutics in development, with a lead program in chemotherapy-induced febrile neutropenia/neutropenic sepsis, the leading cause of treatment-related mortality affecting cancer chemotherapy patients.
PIPELINE OVERVIEW
Our pre-clinical stage asset portfolio
Our exciting pre-clinical stage portfolio includes our lead program - an oral prophylactic treatment for chemically induced febrile neutropenia designed to prevent life threatening infections that occur in immunocompromised patients undergoing cancer chemotherapy.
bottom of page